Lenalidomide-induced tubulointerstitial nephritis in Hodgkin lymphoma

Leuk Lymphoma. 2019 Dec;60(12):3084-3086. doi: 10.1080/10428194.2019.1616187. Epub 2019 May 24.

Authors

Alex Dinh¹, Matthew B Palmer², Jakub Svoboda¹, Jonathan J Hogan³

Affiliations

¹ Department of Medicine, University of Pennsylvania Health System, Philadelphia, PA, USA.
² Department of Medicine and Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.
³ Division of Nephrology, Perelman School of Medicine, University of Pennsylvania, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.

PMID: 31125280
DOI: 10.1080/10428194.2019.1616187

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Biomarkers
Biopsy
Hodgkin Disease / complications*
Hodgkin Disease / diagnosis
Hodgkin Disease / drug therapy
Humans
Immunohistochemistry
Immunologic Factors / adverse effects*
Immunologic Factors / therapeutic use
Lenalidomide / adverse effects*
Lenalidomide / therapeutic use
Male
Nephritis, Interstitial / diagnosis*
Nephritis, Interstitial / etiology*
Symptom Assessment
Tomography, X-Ray Computed
Treatment Outcome
Young Adult

Substances

Biomarkers
Immunologic Factors
Lenalidomide